NCT04679545 is a Phase 2 clinical trial of CBD in Diabetic Peripheral Neuropathic Pain, sponsored by Pure Green.

Who is sponsoring NCT04679545?

NCT04679545 is sponsored by Pure Green.

What drugs are being tested in NCT04679545?

Interventions in NCT04679545: CBD, Placebo.

What condition does NCT04679545 study?

NCT04679545 studies Diabetic Peripheral Neuropathic Pain.

Is NCT04679545 still recruiting?

NCT04679545 is currently status unknown. Last updated 2 February 2021.

Last reviewed 2021-02-02 · How we verify

NCT04679545

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

Status unknown Phase 2 Last updated 2 February 2021

What this trial tests

Phase 2 trial testing CBD in Diabetic Peripheral Neuropathic Pain in 50 participants. Status unknown.

Timeline

10 December 2020

Primary endpoint
1 March 2021

1 April 2021

Quick facts

Lead sponsor	Pure Green
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	10 December 2020
Primary completion	1 March 2021
Estimated completion	1 April 2021
Sites	1 location across United States

Drugs / interventions tested

CBD — full drug profile →
Placebo

Conditions studied

Diabetic Peripheral Neuropathic Pain — all drugs for Diabetic Peripheral Neuropathic Pain →

Sponsor

Pure Green — full company profile →

Who can join

21 and older, any sex, with Diabetic Peripheral Neuropathic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate whether PG-DN-20WS is a better pain reliever in patients with diabetic neuropathic pain of the feet than a placebo.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Applications of Cannabinoids in Neuropathic Pain: An Updated Review.
Arthur P, Kalvala AK, Surapaneni SK, Singh MS. · · 2024 · cited 12× · PMID 37824417 · DOI 10.1615/critrevtherdrugcarriersyst.2022038592
Update on Treating Painful Diabetic Peripheral Neuropathy: A Review of Current US Guidelines with a Focus on the Most Recently Approved Management Options.
Mallick-Searle T, Adler JA. · · 2024 · cited 9× · PMID 38505500 · DOI 10.2147/jpr.s442595

Verify or expand the search:

Other trials of CBD

Trials testing the same drug.

NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT06878417 — Cannabinoids for Osteoarthritis Pain Effectiveness Trial · NA · recruiting
NCT06014424 — Cannabidiol Medication Intervention Trial · Phase 2 · recruiting
NCT05514899 — Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV · Phase 2 · recruiting
NCT05317013 — CBD in Postmenopausal Women With Osteopenia · Phase 1 · terminated

Other recruiting trials for Diabetic Peripheral Neuropathic Pain

Currently open trials in the same condition.

NCT07231419 — Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy · Phase 3 · recruiting
NCT06812117 — A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuro · active not recruiting
NCT06696443 — Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripher · Phase 3 · active not recruiting
NCT06490445 — A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neurop · Phase 2 · recruiting
NCT06619860 — Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy · Phase 2 · recruiting

Other Pure Green trials

Trials by the same sponsor.

NCT04992962 — Cannabinoid Tablets for the Treatment of Pain From Osteoarthritis of the Knee · Phase 2 · unknown
NCT04195269 — Osteoarthritis of the Knee Pain Study Using a CBD and THC Sublingual Tablet · Phase 2 · unknown
NCT04193631 — Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain · Phase 1 · completed
NCT04088929 — The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Periphera · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04679545 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pure Green
Last refreshed: 2 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04679545.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing